What Is Omberacetam (Noopept)?
Omberacetam (also known as Noopept or GVS-111) is a synthetic nootropic dipeptide (N-phenylacetyl-L-prolylglycine ethyl ester) developed in Russia in 1996 for its potent cognitive-enhancing and neuroprotective properties. While structurally distinct from racetams, it's considered part of the nootropic family and functions as a prodrug that converts to the active metabolite cycloprolylglycine (CPG). Research indicates it may enhance memory, learning, and neuroplasticity through BDNF/NGF upregulation and glutamatergic modulation at doses 1000x lower than piracetam.
Mechanism of Action
Rapidly absorbed orally and converted to active metabolite cycloprolylglycine (CPG) which modulates AMPA/NMDA glutamate receptors and enhances cholinergic neurotransmission
Key Benefits
Primary administration route, rapid oral bioavailability, convenient dosing, well-studied in clinical trials, peak absorption within 7 minutes
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Neuroprotection in Alzheimer's Model (2015)
Cellular | Human cortical neurons | β-amyloid/tau phosphorylation model | Multiple concentrations - Neurotrophic Factor Expression (2009)
Animal | Rat | 0.5mg/kg IP | Single dose | Hippocampal analysis - Human Cognitive Enhancement Trial (2008)
Human | 53 patients | 20mg daily vs Piracetam 1200mg | 56 days | Cerebrovascular/post-traumatic conditions - Spatial Memory Restoration Study (2007)
Animal | Mouse Alzheimer's model | 0.01mg/kg daily | 21 days - [Pharmacokinetics of noopept and its active metabolite cycloprolyl glycine in rats]
Boyko SS, Zherdev VP, Shevchenko RV, 2018, Biomed Khim - Noopept normalizes parameters of the incretin system in rats with experimental diabetes
Ostrovskaya RU, Zolotov NN, Ozerova IV, 2014, Bull Exp Biol Med - Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation
Ostrovskaya RU, Vakhitova YV, Kuzmina USh, 2014, J Biomed Sci - The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model
Ostrovskaya RU, Gruden MA, Bobkova NA, 2007, J Psychopharmacol - Selective suppression of the slow-inactivating potassium currents by nootropics in molluscan neurons
Bukanova JV, Solntseva EI, Skrebitsky VG, 2002, Int J Neuropsychopharmacol